$6.95
4.67% today
Nasdaq, Feb 05, 04:18 pm CET
ISIN
US02155H1014
Symbol
ALT

Altimmune, Inc. Stock price

$6.64
-0.61 8.41% 1M
+0.85 14.58% 6M
-0.57 7.91% YTD
-2.75 29.29% 1Y
-1.02 13.32% 3Y
+4.89 279.43% 5Y
-230.66 97.20% 10Y
Nasdaq, Closing price Tue, Feb 04 2025
+0.20 3.11%
ISIN
US02155H1014
Symbol
ALT
Sector
Industry

Key metrics

Market capitalization $472.27m
Enterprise Value $334.62m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 6,692.40
P/S ratio (TTM) P/S ratio 9,445.40
P/B ratio (TTM) P/B ratio 3.54
Revenue growth (TTM) Revenue growth -81.36%
Revenue (TTM) Revenue $50.00k
EBIT (operating result TTM) EBIT $-99.51m
Free Cash Flow (TTM) Free Cash Flow $-78.12m
Cash position $139.42m
EPS (TTM) EPS $-1.55
P/E forward negative
P/S forward 330,489.85
EV/Sales forward 234,163.75
Short interest 34.67%
Show more

Is Altimmune, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

Altimmune, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Altimmune, Inc. forecast:

8x Buy
89%
1x Hold
11%

Analyst Opinions

9 Analysts have issued a Altimmune, Inc. forecast:

Buy
89%
Hold
11%

Financial data from Altimmune, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
0.05 0.05
82% 82%
100%
- Direct Costs 2.10 2.10
-
4,200%
-2.04 -2.04
-
-4,080%
- Selling and Administrative Expenses 16 16
11% 11%
32,040%
- Research and Development Expense 79 79
17% 17%
158,700%
-97 -97
12% 12%
-194,840%
- Depreciation and Amortization 2.10 2.10
-
4,200%
EBIT (Operating Income) EBIT -100 -100
17% 17%
-199,020%
Net Profit -104 -104
32% 32%
-207,040%

In millions USD.

Don't miss a Thing! We will send you all news about Altimmune, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Altimmune, Inc. Stock News

Neutral
GlobeNewsWire
7 days ago
GAITHERSBURG, Md., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference. Details are as follows:
Positive
Seeking Alpha
about one month ago
ALT's end-of-phase 2 meeting with the FDA provided a clear clinical plan for pemvidutide, but the phase 3 program will require 5,000 patients. ALT's $139M in cash is enough to stay afloat for a while at the current rate, but not to fund phase 3, the company needs a partner or a buyout. If ALT can't find a partner or be acquired, then a hefty fund raise awaits investors, which could hit the stock.
Positive
The Motley Fool
about 2 months ago
Altimmune (ALT 3.54%) had some encouraging news to share with the world as the trading week drew near a close on Thursday. The biotech announced that it will soon ascend to an important, specialized stock index; investors greeted this news by trading the company's stock up by more than 3% on the day.
More Altimmune, Inc. News

Company Profile

Altimmune, Inc. is a clinical stage immunotherapeutic biotechnology company. It focuses on the discovery and development of products to stimulate robust and durable immune responses for the prevention and treatment of diseases. The company's portfolio includes RespirVec and Densigen that targets to stimulate the elements of the human immune system to treat respiratory diseases, chronic infections, and cancer. Altimmune was founded in 1997 and is headquartered in Gaithersburg, MD.

Head office United States
CEO Vipin Garg
Employees 59
Founded 1997
Website www.altimmune.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today